British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: A rapid update

British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: A rapid update

The overall aim of the guideline is to provide up‐to‐date, evidence‐based recommendations on the use of biologic therapies targeting TNF (adalimumab, etanercept, certolizumab pegol, infliximab), IL12/23p40 (ustekinumab), IL17A (ixekizumab, secukinumab), IL17RA (brodalumab) and IL23p19 (guselkumab, r...

Full description

Bibliographic Details
Main Authors: Smith, CH, Yiu, ZZ, Bale, T, Burden, AD, Coates, LC, Edwards, W, MacMahon, E, Mahil, S, McGuire, A, Murphy, R, Nelson-Piercy, C, Owen, CM, Parslew, R, Uthman, OA, Woolf, RT, Manounah, L, Ezejimofor, M, Exton, LS, Mohd Mustapa, MF
Other Authors: The British Association of Dermatologists' Clinical Standards Unit
Format: Journal article
Language:English
Published: Wiley 2020
Description
Summary:The overall aim of the guideline is to provide up‐to‐date, evidence‐based recommendations on the use of biologic therapies targeting TNF (adalimumab, etanercept, certolizumab pegol, infliximab), IL12/23p40 (ustekinumab), IL17A (ixekizumab, secukinumab), IL17RA (brodalumab) and IL23p19 (guselkumab, risankizumab, tildrakizumab) in adults, children and young people for the treatment of psoriasis; consideration is given to the specific needs of people with psoriasis and psoriatic arthritis.

Similar Items